United States - English - NLM (National Library of Medicine)

rxhomeo private limited d.b.a. rxhomeo, inc - pummelo (unii: et1tn5w71x) (pummelo - unii:et1tn5w71x) - pummelo 1 [hp_x] - tinnitus condition listed above or as directed by the physician

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - furosemide, quantity: 500 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; lactose monohydrate; silicon dioxide; maltodextrin - indications as at 01 jan 1991 : frusemide in a high-dosage formulation such as urex forte ( 500 mg tablets ) is intended exclusively for patients with severely impaired renal function. for use under strict medical supervision only within a hospital setting (see dosage and administration). high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function e.g. in chronic glomerulonephritis, lupus erythematous and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l / day dialysis has to be used.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - furosemide, quantity: 500 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; silicon dioxide; magnesium stearate; maltodextrin - indications as at 01 jan 1991 : frusemide in a high-dosage formulation such as urex forte ( 500 mg tablets ) is intended exclusively for patients with severely impaired renal function. for use under strict medical supervision only within a hospital setting (see dosage and administration). high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function e.g. in chronic glomerulonephritis, lupus erythematous and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l / day dialysis has to be used.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - furosemide, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; mannitol; sodium hydroxide - frusemide high dosage formulations are intended exclusively for patients with severely impaired renal function. use under strict medical supervision only within a hospital setting (see dosage and administration). high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function, e.g. in chronic glomerular nephritis, lupus erythematosus and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l/day, dialysis has to be used.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - furosemide 500mg;   - tablet - 500 mg - active: furosemide 500mg   excipient: colloidal silicon dioxide lactose magnesium stearate maize starch maltodextrin - frusemide in a high-dosage formulation such as urex forte (500 mg tablets) is intended exclusively for patients with severely impaired renal function. for use under strict medical supervision only within a hospital setting. high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function e.g. in chronic glomerulonephritis, lupus erythematous and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l/day dialysis has to be used.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - furosemide (frusemide) -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - furosemide (frusemide) -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - furosemide, quantity: 250 mg - injection, intravenous infusion - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - frusemide sandoz injection high dose (250 mg/25 ml). frusemide high dose formulation (250 mg/25 ml) is intended exclusively for patients with severely impaired renal function. for use under strict medical supervision only within a hospital setting (see dosage and administration). high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure (e.g. in the post-operative phase and in association with septic infections), in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function (e.g. in chronic glomerular nephritis, lupus erythematous and kimmelstiel-wilson syndrome). if diuresis is less than 2.5 l/day, dialysis has to be used.

Australia - English - Department of Health (Therapeutic Goods Administration)

gunz dental pty ltd - 16670 - bur, dental, diamond - for the removal of decay in teeth.

Australia - English - Department of Health (Therapeutic Goods Administration)

henry schein halas - 38770 - dental material, pulp capping - this product is an internationally recognised dental pulp protector for capping and preserving the vitality of artificially exposed or infected pulps because it aids formation of secondary dentine. it is extensively used in treatment of deep cavities and routine endodontic treatments as this product is x-ray visible.